- Home
- CALX vs VKTX Comparison
CALX vs VKTX Comparison
Compare CALX & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALX
- VKTX
- Stock Information
- Founded
- CALX 1999
- VKTX 2012
- Country
- CALX United States
- VKTX United States
- Employees
- CALX N/A
- VKTX N/A
- Industry
- CALX Telecommunications Equipment
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- CALX Consumer Discretionary
- VKTX Health Care
- Exchange
- CALX Nasdaq
- VKTX Nasdaq
- Market Cap
- CALX 4.2B
- VKTX 3.8B
- IPO Year
- CALX 2010
- VKTX 2015
- Fundamental
- Price
- CALX $53.96
- VKTX $34.40
- Analyst Decision
- CALX Strong Buy
- VKTX Strong Buy
- Analyst Count
- CALX 5
- VKTX 14
- Target Price
- CALX $77.75
- VKTX $87.07
- AVG Volume (30 Days)
- CALX 853.8K
- VKTX 4.3M
- Earning Date
- CALX 10-29-2025
- VKTX 10-22-2025
- Dividend Yield
- CALX N/A
- VKTX N/A
- EPS Growth
- CALX N/A
- VKTX N/A
- EPS
- CALX N/A
- VKTX N/A
- Revenue
- CALX $933,685,000.00
- VKTX N/A
- Revenue This Year
- CALX $19.95
- VKTX N/A
- Revenue Next Year
- CALX $12.89
- VKTX N/A
- P/E Ratio
- CALX N/A
- VKTX N/A
- Revenue Growth
- CALX 4.89
- VKTX N/A
- 52 Week Low
- CALX $28.61
- VKTX $18.92
- 52 Week High
- CALX $71.22
- VKTX $56.25
- Technical
- Relative Strength Index (RSI)
- CALX 30.88
- VKTX 44.88
- Support Level
- CALX $54.51
- VKTX $34.67
- Resistance Level
- CALX $56.85
- VKTX $43.15
- Average True Range (ATR)
- CALX 2.36
- VKTX 2.70
- MACD
- CALX -1.30
- VKTX -0.69
- Stochastic Oscillator
- CALX 12.05
- VKTX 13.85
About CALX Calix Inc
Calix Inc develops, markets and sells its appliance-based platform, cloud and managed services that enable service providers of all types and sizes to innovate and transform their businesses. The company's customers utilize the real-time data and insights from Calix platforms to simplify their business and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty and revenue creates more value for their businesses and communities. The Company's revenue is principally derived in the United States and it also has its presence in Middle East & Africa, Europe, Asia Pacific and other markets.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.